Biweekly Trastuzumab Dosing for HER2-Positive Metastatic Breast Cancer
For HER2-positive metastatic breast cancer, trastuzumab should be administered at 6 mg/kg every 3 weeks (not every 2 weeks) following an 8 mg/kg loading dose, as this is the FDA-approved and evidence-based regimen for convenient, less-frequent dosing. 1
Standard Dosing Regimens
The FDA label clearly defines two approved trastuzumab schedules 1:
- Weekly regimen: 4 mg/kg loading dose, then 2 mg/kg weekly
- Every-3-week regimen: 8 mg/kg loading dose, then 6 mg/kg every 3 weeks
There is no FDA-approved or guideline-supported "biweekly" (every 2 weeks) trastuzumab regimen. The every-3-week schedule was specifically developed and validated to align with chemotherapy agents administered on 3-week cycles (docetaxel, carboplatin, etc.) 1.
First-Line Treatment Approach
Per ASCO 2022 guidelines, the treatment algorithm is straightforward 2:
- First-line standard: Trastuzumab + pertuzumab + taxane (strong recommendation, high-quality evidence)
- Continue chemotherapy for 4-6 months or until maximal response
- Maintain HER2-targeted therapy indefinitely until progression or unacceptable toxicity
The every-3-week trastuzumab schedule (6 mg/kg) is particularly practical when combined with 3-weekly taxanes, as it synchronizes infusion visits and reduces patient burden 3, 4.
Pharmacokinetic Equivalence
Research demonstrates that the every-3-week schedule achieves similar drug exposure and efficacy to weekly dosing 3, 4:
- Response rates: 58-70% in first-line metastatic disease 3
- Median PFS: 9.9 months 3
- Safety profile: Comparable to weekly dosing, with similar cardiac dysfunction rates (2%) 3, 5
Critical Caveats
Cardiac monitoring is mandatory regardless of schedule:
- Baseline LVEF required
- Exclude patients with LVEF <55%, uncontrolled arrhythmias, recent MI, or poorly controlled hypertension 1
- Monitor LVEF every 3 months during treatment
- Permanently discontinue if symptomatic CHF develops or persistent LVEF decline occurs
HER2 testing requirements:
- IHC 3+ OR FISH-positive required 1
- IHC 2+ alone is insufficient (0% response rate in monotherapy studies) 5
Practical Implementation
For metastatic disease, use this sequence:
Cycle 1, Day 1:
- Trastuzumab 8 mg/kg IV + pertuzumab 840 mg IV + taxane (e.g., docetaxel 75 mg/m²)
Every 3 weeks thereafter:
- Trastuzumab 6 mg/kg IV + pertuzumab 420 mg IV + taxane
After 4-6 months of chemotherapy:
- Continue trastuzumab 6 mg/kg + pertuzumab 420 mg IV every 3 weeks as maintenance 2
This approach is supported by the HERA and BCIRG006 trials, which demonstrated that extending treatment duration beyond one year provides no additional benefit, but continuous therapy until progression is standard 1.
If you specifically need a 2-week interval, this would be off-label and lacks supporting pharmacokinetic or efficacy data. The established regimens (weekly or every-3-weeks) should be used instead.